Linklaters

Examples of significant sector projects on which we have advised include:

Pharma

• Auction Sale of Amaxa AG, a bioscience start-up which is a technology leader in cell discovery;
• AstraZeneca on the acquisition of Arrow Therapeutics, Kudos Pharmaceuticals and Cambridge Antibody Technology Group plc;
• Johnson & Johnson on merger control issues in conjunction with its US$1bn public bid to acquire Mentor Corporation;
• Johnson & Johnson on its acquisition of Pfizer’s Consumer Healthcare Business;
• Mayne Pharma Pty Ltd. a PRC entity, in connection with corporate matters;
• Merck on European patent litigation; pharmaceutical company on the acquisition of a controlling stake in a consumer healthcare business in China;
• Sanofi-Aventis on its acquisition of a controlling stake in a greenfield joint venture in China with Minsheng Pharmaceutical Co. Ltd. in relation to the OTC vitamin and mineral supplements business;
• UCB in relation to its recommended cash offer for Celltech Group plc;
• Zydus Cadila (a top five pharmaceutical company in India) in the negotiation of a supply agreement with Abbott Laboratories and in reviewing a PRC joint venture contract of a pharma company.

Biotech

• GPC Biotech AG on its cross border merger with US oncology company Agenix Inc.;
• Auction sale of Amaxa AG, a biosciences start-up which is a technology leader in cell discovery;
• Acting for the financiers on a number of IPOs for companies including Pharmastandard, A&D Pharma, Clinica Baviera S.A., TiGenix NV, NicOx S.A. and Renovo;
• Kempen & Co, a German drug discovery and development company, on a share issue that raised €11.7m and placed 3,452,647 new shares with institutional investors for 4SC;
• US$250m Sterling Biotech Limited Zero Coupon Convertible Bonds due 2012;
• Rights offering of Agennix AG guaranteed by firm commitment agreement of major shareholder dievini visible 1:1 rights issue.